Explore Business Standard
Explore Business Standard
The revenue stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Operating Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
PBDT stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Profit Before Tax stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Net Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This represents a per cent year-on-year *(YoY) decline for the same year.
| Category | Q3 FY25-26 | Q3 FY24-25 | Change % | FY24-25 | FY23-24 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 6,864.50 | 5,269.10 | 30.28 | 23,241.50 | 19,547.40 | 18.90 |
| Expenses | 5,133.00 | 3,881.80 | 32.23 | 16,402.60 | 14,177.30 | 15.70 |
| Other Income | 111.40 | 57.50 | 93.74 | 269.50 | 307.10 | -12.24 |
| Operating Profit | 241.30 | 89.50 | 169.61 | 7,108.40 | 5,677.20 | 25.21 |
| Depreciation | 359.60 | 229.00 | 57.03 | 915.80 | 764.10 | 19.85 |
| Interest | 129.90 | 32.00 | 305.94 | 165.90 | 81.20 | 104.31 |
| Profit Before Tax | 1,411.20 | 1,205.70 | 17.04 | 6,026.70 | 4,831.90 | 24.73 |
| Tax | 388.30 | 179.50 | 116.32 | 2,049.30 | 1,492.60 | 37.30 |
| Net Profit | 1,127.00 | 1,023.80 | 10.08 | 4,614.80 | 3,854.40 | 19.73 |
| Category | Q3 FY25-26 | Q3 FY24-25 | Change % | FY24-25 | FY23-24 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 2,283.60 | 2,515.90 | -9.23 | 15,116.30 | 10,818.70 | 39.72 |
| Expenses | 2,144.70 | 1,867.40 | 14.85 | 7,380.00 | 6,768.60 | 9.03 |
| Other Income | 473.80 | 77.50 | 511.35 | 696.20 | 1,084.80 | -35.82 |
| Operating Profit | 1,989.70 | 2,086.70 | -4.65 | 8,432.50 | 5,134.90 | 64.22 |
| Depreciation | 144.30 | 131.60 | 9.65 | 523.90 | 504.40 | 3.87 |
| Interest | 116.00 | 97.20 | 19.34 | 463.90 | 390.70 | 18.74 |
| Profit Before Tax | 352.40 | 497.20 | -29.12 | 7,444.70 | 4,239.80 | 75.59 |
| Tax | 55.90 | 26.60 | 110.15 | 1,582.50 | 934.30 | 69.38 |
| Net Profit | 296.50 | 470.60 | -37.00 | 5,774.90 | 3,441.50 | 67.80 |
| Category | Q3 FY25-26 | Q2 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 6,864.50 | 6,123.20 | 12.11 |
| Expenses | 5,133.00 | 4,141.60 | 23.94 |
| Other Income | 111.40 | 109.00 | 2.20 |
| Operating Profit | 241.30 | 210.30 | 14.74 |
| Depreciation | 359.60 | 301.90 | 19.11 |
| Interest | 129.90 | 101.30 | 28.23 |
| Profit Before Tax | 1,411.20 | 1,692.60 | -16.63 |
| Tax | 388.30 | 454.00 | -14.47 |
| Net Profit | 1,127.00 | 1,292.80 | -12.82 |
| Category | Q3 FY25-26 | Q2 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 2,283.60 | 2,871.20 | -20.47 |
| Expenses | 2,144.70 | 1,719.30 | 24.74 |
| Other Income | 473.80 | 541.50 | -12.50 |
| Operating Profit | 1,989.70 | 3,005.10 | -33.79 |
| Depreciation | 144.30 | 136.00 | 6.10 |
| Interest | 116.00 | 113.80 | 1.93 |
| Profit Before Tax | 352.40 | 1,443.60 | -75.59 |
| Tax | 55.90 | 287.00 | -80.52 |
| Net Profit | 296.50 | 1,156.60 | -74.36 |
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Data not available.
| Company | 1 Day | 1 Week | 1 Month | 3 Months | 6 Month | 1 Year |
|---|---|---|---|---|---|---|
| Data Not Found | ||||||
Zydus Lifesciences on Wednesday said it has launched a biosimilar for the treatment of osteoporosis and the prevention of skeletal complications in cancer patients. The company has launched Zyrifa, a Denosumab biosimilar. Denosumab is a monoclonal antibody with several indications related to bone health, primarily in the treatment of osteoporosis and the prevention of skeletal complications in cancer patients. This will provide access and treat patients with bone metastases due to breast, prostate, lung, myeloma, kidney, thyroid, head & neck, and other solid tumours, the Ahmedabad-based drug firm said in a regulatory filing. Metastases, is when the cancer spreads to the bones and other organs in the body indicating an advanced stage of cancer. The company said it has priced 'Zyrifa' at MRP of Rs 12,495. Sharvil P Patel, Managing Director, Zydus Lifesciences Ltd said that with Denosumab 120 mg SC, the company aims to bring access, affordability of medication in cancer patients ...
Zydus Lifesciences Ltd on Wednesday said it has entered into an exclusive licensing and commercialisation agreement with RK Pharma Inc of the US for a new sterile injectable oncology supportive care product for the US market. Under the terms of this agreement, RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA (new drug application) submission and commercialisation of the product in the US, the company said in a regulatory filing. The product is expected to be filed in 2026 and will provide a formulation that is intended to provide reduced dosing error and enhanced compliance of healthcare professionals, it added. "This partnership reinforces our commitment to delivering high-quality, affordable medicines and improving patient care," Zydus Lifesciences Managing Director Sharvil Patel said. RK Pharma Founder and Executive Chairman Ravishanker Kovi said, "Our collaboration with Zydus, a company with robust regulatory expertise and
